{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:21:36Z","timestamp":1785842496474,"version":"3.56.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ygyno.2014.09.009","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T19:19:07Z","timestamp":1410981547000},"page":"3-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":269,"title":["Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions"],"prefix":"10.1016","volume":"136","author":[{"given":"Johnathan M.","family":"Lancaster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Bethan","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3370-0161","authenticated-orcid":false,"given":"Lee-may","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2014.09.009_bb0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","article-title":"Hereditary cancer predisposition syndromes","volume":"23","author":"Garber","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2014.09.009_bb0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.AOG.0000269050.79143.84","article-title":"The role of genetic testing for cancer susceptibility in gynecologic practice","volume":"110","author":"Karlan","year":"2007","journal-title":"Obstet Gynecol"},{"issue":"23","key":"10.1016\/j.ygyno.2014.09.009_bb0015","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","article-title":"Breast and ovarian cancer","volume":"348","author":"Wooster","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ygyno.2014.09.009_bb0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra012242","article-title":"Hereditary colorectal cancer","volume":"348","author":"Lynch","year":"2003","journal-title":"N Engl J Med"},{"issue":"5182","key":"10.1016\/j.ygyno.2014.09.009_bb0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"issue":"6559","key":"10.1016\/j.ygyno.2014.09.009_bb0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2014.09.009_bb0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/ng0696-238","article-title":"BRCA2 mutations in primary breast and ovarian cancers","volume":"13","author":"Lancaster","year":"1996","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ygyno.2014.09.009_bb0040","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0092-8674(93)90546-3","article-title":"The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer","volume":"75","author":"Fishel","year":"1993","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ygyno.2014.09.009_bb0045","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0092-8674(93)90330-S","article-title":"Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer","volume":"75","author":"Leach","year":"1993","journal-title":"Cell"},{"issue":"6468","key":"10.1016\/j.ygyno.2014.09.009_bb0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/368258a0","article-title":"Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer","volume":"368","author":"Bronner","year":"1994","journal-title":"Nature"},{"issue":"5153","key":"10.1016\/j.ygyno.2014.09.009_bb0055","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1126\/science.8128251","article-title":"Mutation of a mutL homolog in hereditary colon cancer","volume":"263","author":"Papadopoulos","year":"1994","journal-title":"Science"},{"issue":"44","key":"10.1016\/j.ygyno.2014.09.009_bb0060","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.ygyno.2014.09.009_bb0065","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.ygyno.2014.09.009_bb0070","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"5645","key":"10.1016\/j.ygyno.2014.09.009_bb0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ygyno.2014.09.009_bb0080","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10689-013-9615-1","article-title":"Cancer risk in Lynch syndrome","volume":"12","author":"Barrow","year":"2013","journal-title":"Fam Cancer"},{"issue":"20","key":"10.1016\/j.ygyno.2014.09.009_bb0085","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1200\/JCO.2001.19.20.4074","article-title":"MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families","volume":"19","author":"Vasen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2014.09.009_bb0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.gastro.2004.03.068","article-title":"Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance","volume":"127","author":"Hendriks","year":"2004","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.ygyno.2014.09.009_bb0095","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1200\/JCO.2004.02.033","article-title":"Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium","volume":"22","author":"Plaschke","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.09.009_bb0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1399-0004.2008.01035.x","article-title":"Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations","volume":"74","author":"Barrow","year":"2008","journal-title":"Clin Genet"},{"issue":"2","key":"10.1016\/j.ygyno.2014.09.009_bb0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-0004.2008.01125.x","article-title":"Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations","volume":"75","author":"Barrow","year":"2009","journal-title":"Clin Genet"},{"issue":"1","key":"10.1016\/j.ygyno.2014.09.009_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1897-4287-7-17","article-title":"Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management","volume":"7","author":"Ramsoekh","year":"2009","journal-title":"Hered Cancer Clin Pract"},{"issue":"5","key":"10.1016\/j.ygyno.2014.09.009_bb0115","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2009.07.039","article-title":"Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome","volume":"137","author":"Stoffel","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ygyno.2014.09.009_bb0120","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jnci\/djp473","article-title":"Risks of Lynch syndrome cancers for MSH6 mutation carriers","volume":"102","author":"Baglietto","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"10.1016\/j.ygyno.2014.09.009_bb0125","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ygyno.2014.09.009_bb0130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10689-012-9552-4","article-title":"Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation","volume":"11","author":"Therkildsen","year":"2012","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2014.09.009_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.gastro.2008.04.026","article-title":"The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations","volume":"135","author":"Senter","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ygyno.2014.09.009_bb0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10897-008-9187-7","article-title":"Cowden syndrome: a critical review of the clinical literature","volume":"18","author":"Pilarski","year":"2009","journal-title":"J Genet Couns"},{"issue":"1","key":"10.1016\/j.ygyno.2014.09.009_bb0145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1897-4287-8-6","article-title":"Cancer and Lhermitte\u2013Duclos disease are common in Cowden syndrome patients","volume":"8","author":"Riegert-Johnson","year":"2010","journal-title":"Hered Cancer Clin Pract"},{"issue":"2","key":"10.1016\/j.ygyno.2014.09.009_bb0150","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ygyno.2014.09.009_bb0155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jmedgenet-2012-101339","article-title":"High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome","volume":"50","author":"Bubien","year":"2013","journal-title":"J Med Genet"},{"issue":"8","key":"10.1016\/j.ygyno.2014.09.009_bb0160","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","article-title":"Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations","volume":"27","author":"Gonzalez","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6663","key":"10.1016\/j.ygyno.2014.09.009_bb0165","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/34432","article-title":"A serine\/threonine kinase gene defective in Peutz\u2013Jeghers syndrome","volume":"391","author":"Hemminki","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2014.09.009_bb0170","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2014.09.009_bb0175","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2224","article-title":"Germline RAD51C mutations confer susceptibility to ovarian cancer","volume":"44","author":"Loveday","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ygyno.2014.09.009_bb0180","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.955","article-title":"Mutations in BRIP1 confer high risk of ovarian cancer","volume":"43","author":"Rafnar","year":"2011","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.ygyno.2014.09.009_bb0185","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","article-title":"Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer","volume":"71","author":"Casadei","year":"2011","journal-title":"Cancer Res"},{"issue":"44","key":"10.1016\/j.ygyno.2014.09.009_bb0190","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.ygyno.2014.09.009_bb0195","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2010.1910","article-title":"DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli\u2013Leydig cell tumors","volume":"305","author":"Rio Frio","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ygyno.2014.09.009_bb0200","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ejhg.2013.215","article-title":"Germ-line deletion in DICER1 revealed by a novel MLPA assay using synthetic oligonucleotides","volume":"22","author":"Sabbaghian","year":"2014","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.ygyno.2014.09.009_bb0205","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5114\/pjp.2013.39331","article-title":"Ovarian small cell carcinoma of hypercalcemic type \u2014 evidence of germline origin and SMARCA4 gene inactivation. a pilot study","volume":"64","author":"Kupryja\u0144czyk","year":"2013","journal-title":"Pol J Pathol"},{"issue":"5","key":"10.1016\/j.ygyno.2014.09.009_bb0210","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng.2922","article-title":"Recurrent SMARCA4 mutations in small cell carcinoma of the ovary","volume":"46","author":"Jelinic","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ygyno.2014.09.009_bb0215","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/ng.2931","article-title":"Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type","volume":"46","author":"Witkowski","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ygyno.2014.09.009_bb0220","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/ng.2928","article-title":"Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4","volume":"46","author":"Ramos","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ygyno.2014.09.009_bb0225","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa031759","article-title":"Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition","volume":"351","author":"Kriege","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ygyno.2014.09.009_bb0230","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","article-title":"Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination","volume":"292","author":"Warner","year":"2004","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ygyno.2014.09.009_bb0235","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0016-5085(00)70168-5","article-title":"Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer","volume":"118","author":"Jarvinen","year":"2000","journal-title":"Gastroenterology"},{"issue":"25","key":"10.1016\/j.ygyno.2014.09.009_bb0240","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ygyno.2014.09.009_bb0245","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","article-title":"Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update","volume":"118","author":"Gronwald","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.09.009_bb0250","unstructured":"Available from: http:\/\/files.shareholder.com\/downloads\/MYGN\/2784875405x0x661835\/b6aec217-2edd-4afc-be8e-d0a36414ce91\/AnalystDay_Presentation_FINAL.pdf."},{"issue":"9","key":"10.1016\/j.ygyno.2014.09.009_bb0255","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ygyno.2014.09.009_bb0260","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2014.09.009_bb0265","doi-asserted-by":"crossref","first-page":"e1003212","DOI":"10.1371\/journal.pgen.1003212","article-title":"Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk","volume":"9","author":"Couch","year":"2013","journal-title":"PLoS Genet"},{"issue":"4","key":"10.1016\/j.ygyno.2014.09.009_bb0270","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/PPO.0b013e3182610e38","article-title":"Direct-to-consumer personal genome testing and cancer risk prediction","volume":"18","author":"Bellcross","year":"2012","journal-title":"Cancer J"},{"issue":"23","key":"10.1016\/j.ygyno.2014.09.009_bb0275","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1001\/jama.297.23.2587","article-title":"Limited family structure and BRCA gene mutation status in single cases of breast cancer","volume":"297","author":"Weitzel","year":"2007","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ygyno.2014.09.009_bb0280","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1001\/jama.297.23.2637","article-title":"Modeling genetic risk of breast cancer","volume":"297","author":"Kauff","year":"2007","journal-title":"JAMA"},{"issue":"34","key":"10.1016\/j.ygyno.2014.09.009_bb0285","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1200\/JCO.2005.02.9199","article-title":"Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers","volume":"23","author":"Kramer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.09.009_bb0305","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/01.AOG.0000456325.50739.72","article-title":"Practice Bulletin No. 147. Society of Obstetricians and Gynecologists","volume":"124","author":"Lynch","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.ygyno.2014.09.009_bb0290","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.09.009_bb0295","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/302714","article-title":"Laws restricting health insurers' use of genetic information: impact on genetic discrimination","volume":"66","author":"Hall","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.ygyno.2014.09.009_bb0300","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajmg.a.20025","article-title":"Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination","volume":"120A","author":"Armstrong","year":"2003","journal-title":"Am J Med Genet A"}],"updated-by":[{"DOI":"10.1016\/j.ygyno.2015.06.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000}}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814013122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814013122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T23:58:31Z","timestamp":1565827111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814013122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0090825814013122"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.009","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718883352.793527252","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}